These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 26111924)

  • 1. On developing a pragmatic strategy for clinical trials: A case study of hepatocellular carcinoma.
    Gandhi M; Tan SB; Chung Yaw Fui A; Machin D
    Contemp Clin Trials; 2015 Jul; 43():252-9. PubMed ID: 26111924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis.
    Chua TC; Saxena A; Chu F; Butler SP; Quinn RJ; Glenn D; Morris DL
    Int J Clin Oncol; 2011 Apr; 16(2):125-32. PubMed ID: 21061140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis.
    Gong L; Shi L; Sun J; Yuan WS; Chen JF; Liu P; Gong F; Dong JH
    Nucl Med Commun; 2014 May; 35(5):484-92. PubMed ID: 24492679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial.
    Chung AY; Ooi LL; Machin D; Tan SB; Goh BK; Wong JS; Chen YM; Li PC; Gandhi M; Thng CH; Yu SW; Tan BS; Lo RH; Htoo AM; Tay KH; Sundram FX; Goh AS; Chew SP; Liau KH; Chow PK; Tay KH; Tan YM; Cheow PC; Ho CK; Soo KC
    World J Surg; 2013 Jun; 37(6):1356-61. PubMed ID: 23463394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis of adjuvant i(131) lipiodol after excision of hepatocellular carcinoma.
    Furtado R; Crawford M; Sandroussi C
    Ann Surg Oncol; 2014 Aug; 21(8):2700-7. PubMed ID: 24743904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival.
    Lau WY; Lai EC; Leung TW; Yu SC
    Ann Surg; 2008 Jan; 247(1):43-8. PubMed ID: 18156922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter arterial infusion chemotherapy prior to radiofrequency thermal ablation for single hepatocellular carcinoma reduces the risk of intrahepatic distant recurrence.
    Nishikawa H; Osaki Y; Kita R; Kimura T; Inuzuka T; Takeda H; Nakajima J; Matsuda F; Sakamoto A; Henmi S; Hatamaru K; Saito S; Nasu A
    Int J Oncol; 2012 Sep; 41(3):903-9. PubMed ID: 22692851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.
    Boucher E; Corbinais S; Rolland Y; Bourguet P; Guyader D; Boudjema K; Meunier B; Raoul JL
    Hepatology; 2003 Nov; 38(5):1237-41. PubMed ID: 14578862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study.
    Brans B; De Winter F; Defreyne L; Troisi R; Vanlangenhove P; Van Vlierberghe H; Lambert B; Praet M; de Hemptinne B; Dierckx RA
    Cancer Biother Radiopharm; 2001 Aug; 16(4):333-8. PubMed ID: 11603004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Intraarterial Lipiodol or ¹³¹I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial.
    Dumortier J; Decullier E; Hilleret MN; Bin-Dorel S; Valette PJ; Boillot O; Partensky C; Letoublon C; Ducerf C; Leroy V; Vuillez JP; Borson-Chazot F
    J Nucl Med; 2014 Jun; 55(6):877-83. PubMed ID: 24722530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131-lipiodol therapy in hepatic tumours.
    Ahmadzadehfar H; Sabet A; Wilhelm K; Biersack HJ; Risse J
    Methods; 2011 Nov; 55(3):246-52. PubMed ID: 21664971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant systemic drug therapy and recurrence of hepatocellular carcinoma following curative resection.
    Zhong Y; Liu B; Deng M; Xu R
    Drug Discov Ther; 2013 Aug; 7(4):164-6. PubMed ID: 24071579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and prognostic factors after adjuvant
    Olesinski J; Mithieux F; Guillaud O; Hilleret MN; Lombard-Bohas C; Henry L; Boillot O; Walter T; Partensky C; Paliard P; Valette PJ; Vuillez JP; Borson-Chazot F; Scoazec JY; Dumortier J
    Ann Nucl Med; 2017 Jun; 31(5):379-389. PubMed ID: 28342103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant treatments for resectable hepatocellular carcinoma.
    Ishii H; Yamamoto J; Ikari T
    J Hepatobiliary Pancreat Surg; 2008; 15(5):459-62. PubMed ID: 18836796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis.
    Tabone M; Vigano' L; Ferrero A; Pellerito R; Carbonatto P; Capussotti L
    Eur J Surg Oncol; 2007 Feb; 33(1):61-6. PubMed ID: 17175128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma.
    Izumi R; Shimizu K; Miyazaki I
    Hepatogastroenterology; 1996; 43(12):1415-20. PubMed ID: 8975941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter arterial embolic therapies for hepatocellular carcinoma: a literature review.
    Nishikawa H; Kita R; Kimura T; Osaki Y
    Anticancer Res; 2014 Dec; 34(12):6877-86. PubMed ID: 25503113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection.
    Tanaka K; Shimada H; Togo S; Takahashi T; Endo I; Sekido H; Yoshida T
    Hepatogastroenterology; 1999; 46(26):1083-8. PubMed ID: 10370671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma.
    Mathurin P; Raynard B; Dharancy S; Kirzin S; Fallik D; Pruvot FR; Roumilhac D; Canva V; Paris JC; Chaput JC; Naveau S
    Aliment Pharmacol Ther; 2003 May; 17(10):1247-61. PubMed ID: 12755838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of hepatocellular cancer with iodine-131-Lipiodol.
    Risse JH; Menzel C; Grünwald F; Strunk H; Biersack HJ; Palmedo H
    Rom J Gastroenterol; 2004 Jun; 13(2):119-24. PubMed ID: 15229776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.